Search clinical trials for: Intron

Total 171 results

Merck Sharp & Dohme LLC

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Chronic Myelogenous Leukemia
Merck Sharp & Dohme LLC

Terminated

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

Melanoma
Merck Sharp & Dohme LLC

Completed

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Neoplasms
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center

Completed

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
Case Comprehensive Cancer Center

Completed

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Recurrent Intraocular Melanoma

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Lymphoma

United States
M.D. Anderson Cancer Center
VioQuest Pharmaceuticals

Completed

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

Advanced Cancer | Solid Tumors

United States
M.D. Anderson Cancer Center
Schering-Plough; Eisai Inc.

Terminated

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Melanoma

United States
William Carson
Schering-Plough

Completed

Recombinant Interferon Alfa-2b in Treating Patients With Melanoma

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
M.D. Anderson Cancer Center
Schering-Plough

Terminated

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Leukemia, Myeloid, Philadelphia-Positive

United States
M.D. Anderson Cancer Center

Completed

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Hematologic Neoplasms | Lymphoma, T-Cell | Mycosis Fungoides

United States
Merck Sharp & Dohme LLC

Terminated

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Leukemia

United States
Sun Yat-sen University

Unknown

A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma

China
Peking University Cancer Hospital & Institute

Unknown

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Melanoma

China
Masonic Cancer Center, University of Minnesota

Terminated

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Leukemia

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Study of PEG-Intron for Plexiform Neurofibromas

Plexiform Neurofibroma

United States
Lisa H. Butterfield, Ph.D.
National Cancer Institute (NCI)

Completed

Multiple Antigen-Engineered DC Vaccine for Melanoma

Melanoma

United States
Coordinación de Investigación en Salud, Mexico
University of Guadalajara; Instituto Mexicano del Seguro Social

Completed

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Conjunctival Intraepithelial Neoplasia | Corneal Intraepithelial Neoplasia

Mexico
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Beth Israel Deaconess Medical Center
Schering-Plough

Completed

Study of Long-term Peg Intron vs. Colchicine in Non-responders. (COPILOT)

Cirrhosis | Hepatitis C Virus | Advanced Fibrosis

United States
Merck Sharp & Dohme LLC

Completed

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Melanoma
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

Melanoma

United States
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
Merck Sharp & Dohme LLC

Completed

PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

Hepatitis B, Chronic (CHB)
Merck Sharp & Dohme LLC

Terminated

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

Liver Transplantation | Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Terminated

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Fibrosis | Liver Cirrhosis | Hepatitis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

Cirrhosis | Chronic Hepatitis C
Virginia Commonwealth University
Ortho Biotech, Inc.

Completed

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

Hepatitis C

United States
Forest Laboratories

Completed

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Cystic Fibrosis | Pancreatic Insufficiency

United States
Merck Sharp & Dohme LLC

Completed

Phase III PEG-Intron in HIV-infected Patients (Study P00738)

HIV Infections | AIDS
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
University of North Carolina, Chapel Hill
Tibotec Pharmaceutical Limited

Completed

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Hepatitis C

United States
Emory University
Bayer

Completed

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Leukemia

United States
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Hepatitis C, Chronic

United States
M.D. Anderson Cancer Center
Novartis

Completed

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myeloid, Chronic

United States

3

Subscribe